KR20180064507A - 선택적 nr2b 길항제 - Google Patents

선택적 nr2b 길항제 Download PDF

Info

Publication number
KR20180064507A
KR20180064507A KR1020187013128A KR20187013128A KR20180064507A KR 20180064507 A KR20180064507 A KR 20180064507A KR 1020187013128 A KR1020187013128 A KR 1020187013128A KR 20187013128 A KR20187013128 A KR 20187013128A KR 20180064507 A KR20180064507 A KR 20180064507A
Authority
KR
South Korea
Prior art keywords
mmol
column
flow rate
compound
substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020187013128A
Other languages
English (en)
Korean (ko)
Inventor
이마둘 이슬람
스리니바산 탕가티루파티
자야쿠마르 산카라 와리에르
스리니바스 체루쿠
푸르니마 셰티
존 이. 마코르
Original Assignee
브리스톨-마이어스 스큅 컴퍼니
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 브리스톨-마이어스 스큅 컴퍼니 filed Critical 브리스톨-마이어스 스큅 컴퍼니
Publication of KR20180064507A publication Critical patent/KR20180064507A/ko
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5355—Non-condensed oxazines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/09—Geometrical isomers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
KR1020187013128A 2015-10-14 2016-10-13 선택적 nr2b 길항제 Pending KR20180064507A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN3309DE2015 2015-10-14
IN3309/DEL/2015 2015-10-14
PCT/US2016/056716 WO2017066368A1 (en) 2015-10-14 2016-10-13 Selective nr2b antagonists

Publications (1)

Publication Number Publication Date
KR20180064507A true KR20180064507A (ko) 2018-06-14

Family

ID=57208377

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020187013128A Pending KR20180064507A (ko) 2015-10-14 2016-10-13 선택적 nr2b 길항제

Country Status (13)

Country Link
US (2) US10501451B2 (cg-RX-API-DMAC10.html)
EP (1) EP3362447B1 (cg-RX-API-DMAC10.html)
JP (1) JP6843853B2 (cg-RX-API-DMAC10.html)
KR (1) KR20180064507A (cg-RX-API-DMAC10.html)
CN (1) CN108368101B (cg-RX-API-DMAC10.html)
AU (1) AU2016340239A1 (cg-RX-API-DMAC10.html)
BR (1) BR112018007181A2 (cg-RX-API-DMAC10.html)
CA (1) CA3001894A1 (cg-RX-API-DMAC10.html)
EA (1) EA201890764A1 (cg-RX-API-DMAC10.html)
ES (1) ES2822830T3 (cg-RX-API-DMAC10.html)
IL (1) IL258611A (cg-RX-API-DMAC10.html)
MX (1) MX2018004257A (cg-RX-API-DMAC10.html)
WO (1) WO2017066368A1 (cg-RX-API-DMAC10.html)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2018004256A (es) * 2015-10-14 2018-05-16 Squibb Bristol Myers Co Antagonistas de receptor de n-metil-d-aspartato subtipo 2b (nr2b) selectivos.
EA202191014A1 (ru) * 2018-10-17 2021-11-09 Бёрингер Ингельхайм Интернациональ Гмбх Производные 4-пиразин-2-илметил-морфолина и их применение в качестве лекарственного средства
TW202035396A (zh) * 2018-10-17 2020-10-01 德商百靈佳殷格翰國際股份有限公司 4-吡啶基甲基-嗎啉衍生物及其作為藥物之用途
CN112888684B (zh) * 2018-10-17 2023-10-10 勃林格殷格翰国际有限公司 4-嘧啶-5-基甲基-吗啉衍生物及其作为药物的用途
US12398143B2 (en) 2019-06-04 2025-08-26 Boehringer Ingelheim International Gmbh Imidazopyrazine derivatives and the use thereof as medicament
EP4255419A1 (en) * 2020-12-04 2023-10-11 Novartis AG Dosage regimen for a nr2b-nmda receptor nam for the treatment of depression
CN113620896A (zh) * 2021-08-31 2021-11-09 青岛科技大学 2-(2-氯苯基)甲基-4,4-二甲基-3-异恶唑酮的制备方法
CN116063200A (zh) * 2022-12-12 2023-05-05 华南理工大学 一种异噁唑啉宠物用杀虫剂氟雷拉纳中间体及其制备方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6476041B1 (en) 1999-10-29 2002-11-05 Merck & Co., Inc. 1,4 substituted piperidinyl NMDA/NR2B antagonists
US7022728B2 (en) 2001-03-09 2006-04-04 Abbott Laboratories Benzimidazoles that are useful in treating male sexual dysfunction
JPWO2003035641A1 (ja) 2001-10-22 2005-02-10 塩野義製薬株式会社 新規カルバモイルピロリドン誘導体
KR20060017839A (ko) 2003-06-04 2006-02-27 머크 앤드 캄파니 인코포레이티드 Nmda/nr2b 길항제로서 3-플루오로-피페리딘
MXPA06003748A (es) 2003-10-08 2006-06-14 Pfizer Compuestos de lactama condensada.
US20070185168A1 (en) * 2004-04-07 2007-08-09 Takai Haruki S Piperidine derivatives
JPWO2006137465A1 (ja) * 2005-06-24 2009-01-22 塩野義製薬株式会社 含窒素複素環誘導体
EP2520567A3 (en) 2006-02-23 2012-12-12 Shionogi & Co., Ltd. Nitrogen-containing heterocycle derivatives substituted with cyclic group
KR20100045983A (ko) 2007-06-29 2010-05-04 에모리 유니버시티 신경보호를 위한 nmda 수용체 길항물질
JP2009067784A (ja) * 2007-08-21 2009-04-02 Shionogi & Co Ltd 環式基で置換された含窒素複素環誘導体を含有する鎮痛剤
SG10201501050RA (en) * 2010-02-11 2015-04-29 Univ Northwestern Secondary Structure Stabilized NMDA Receptor Modulators And Uses Thereof
US9221796B2 (en) * 2014-01-09 2015-12-29 Bristol-Myers Squibb Company Selective NR2B antagonists
US9187506B2 (en) 2014-01-09 2015-11-17 Bristol-Myers Squibb Company (R)-3-((3S,4S)-3-fluoro-4-(4-hydroxyphenyl)piperidin-1-yl)-1-(4-methylbenzyl)pyrrolidin-2-one and its prodrugs for the treatment of psychiatric disorders

Also Published As

Publication number Publication date
US10954225B2 (en) 2021-03-23
CN108368101B (zh) 2022-03-15
EP3362447A1 (en) 2018-08-22
MX2018004257A (es) 2018-05-16
CN108368101A (zh) 2018-08-03
BR112018007181A2 (pt) 2018-10-16
EA201890764A1 (ru) 2018-09-28
IL258611A (en) 2018-06-28
ES2822830T3 (es) 2021-05-05
EP3362447B1 (en) 2020-08-26
US20200115370A1 (en) 2020-04-16
US10501451B2 (en) 2019-12-10
JP6843853B2 (ja) 2021-03-17
AU2016340239A1 (en) 2018-05-31
WO2017066368A1 (en) 2017-04-20
CA3001894A1 (en) 2017-04-20
JP2018530582A (ja) 2018-10-18
US20180312495A1 (en) 2018-11-01

Similar Documents

Publication Publication Date Title
JP6843853B2 (ja) 選択的nr2bアンタゴニスト
ES2459318T3 (es) Antagonistas no esteroideos del receptor mineralocorticoide derivados de la 6H-dibenzo[B,E]oxepina
KR102311518B1 (ko) 선택적 nr2b 길항제
KR102331120B1 (ko) 정신 장애의 치료를 위한 (r)-3-((3s,4s)-3-플루오로-4-(4-히드록시페닐)피페리딘-1-일)-1-(4-메틸벤질)피롤리딘-2-온 및 그의 전구약물
JP6938485B2 (ja) 選択的nr2bアンタゴニスト
AU2018379438A1 (en) Imidazopyridine derivatives and the use thereof as medicament

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20180509

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20211012

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20231201

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20240820